Basking in the sun: nine solar policy essentials
Learn moreInstitutional Investments
Co-head of Healthcare Ventures John E. Milad comments on the Mansion House reforms
18/7/23
5 min
Healthcare
Insight
Downing's Co-head of Healthcare Ventures, John E. Milad, recently spoke to Stephen Hansen, who is the Director of Biopharma Intelligence, about the recent Mansion House reforms.
Under the Mansion House Compact, the voluntary agreement unveiled last week between the government and nine of the largest U.K. defined contribution pension funds, the funds agreed to allocate at least 5% of investments specifically in unlisted equities by 2030.
John discusses the direction of pension fund capital against the backdrop of these crucial reforms.
Read the full article (please note the original article is behind a paywall)
Share
Contents
See full contents
Downing's Co-head of Healthcare Ventures, John E. Milad, recently spoke to Stephen Hansen, who is the Director of Biopharma Intelligence, about the recent Mansion House reforms.
Under the Mansion House Compact, the voluntary agreement unveiled last week between the government and nine of the largest U.K. defined contribution pension funds, the funds agreed to allocate at least 5% of investments specifically in unlisted equities by 2030.
John discusses the direction of pension fund capital against the backdrop of these crucial reforms.
Read the full article (please note the original article is behind a paywall)
Share
Downing's Co-head of Healthcare Ventures, John E. Milad, recently spoke to Stephen Hansen, who is the Director of Biopharma Intelligence, about the recent Mansion House reforms.
Under the Mansion House Compact, the voluntary agreement unveiled last week between the government and nine of the largest U.K. defined contribution pension funds, the funds agreed to allocate at least 5% of investments specifically in unlisted equities by 2030.
John discusses the direction of pension fund capital against the backdrop of these crucial reforms.
Read the full article (please note the original article is behind a paywall)
Share
Downing's Co-head of Healthcare Ventures, John E. Milad, recently spoke to Stephen Hansen, who is the Director of Biopharma Intelligence, about the recent Mansion House reforms.
Under the Mansion House Compact, the voluntary agreement unveiled last week between the government and nine of the largest U.K. defined contribution pension funds, the funds agreed to allocate at least 5% of investments specifically in unlisted equities by 2030.
John discusses the direction of pension fund capital against the backdrop of these crucial reforms.
Read the full article (please note the original article is behind a paywall)
Please fill out the form to download the full report
Share
Sign up to stay up to date with the latest insights and investment opportunities
Learn more
Downing LLP does not provide advice or make personal recommendations and investors are strongly urged to seek independent advice before investing. Investments offered on this website carry a higher risk than many other types of investment and prospective investors should be aware that capital is at risk and the value of their investment may go down as well as up. Any investment should only be made on the basis of the relevant product literature and your attention is drawn to the risk, fees and taxation factors contained therein. Tax treatment depends on individual circumstances of each investor and may be subject to change in the future. Past performance is not a reliable indicator of future performance. Downing LLP is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 545025). Registered in England No. OC341575. Registered Office: Downing, 10 Lower Thames Street, London, EC3R 6AF.
VAT Number: 112 940 149